Andrey Soares
@SoaresAndrey
Followers
3K
Following
7K
Statuses
5K
Scientific Committee Member LACOG - GU | Medical Oncologist at Hospital Albert Einstein | Owner and founder BIO | Following or RT does not mean endorsement
São Paulo, Brasil
Joined July 2009
Great data, but not much different from #PEACE3 trial, with more toxicity. Would like to see the subsequent treatment accordingly with HRR status and a deep molecular analysis in the HRR -ve/unknown populatiom #GU25
Results of TALAPRO-2 presented by @neerajaiims #GU25 PARPi + ARPI combination showing clinically meaningful benefit in OS for mCRPC 45.8 mos 8.8 mos longer than active control No new safety findings with median duration of treatment 19.7 mos
0
2
6
RT @DrYukselUrun: What should we measure, and how should we measure it? A fundamental question.
0
2
0
Is ICI+TKI better than Sunitinib in fav-risk #mRCC? In the abscense of biomarkers, this RWE gives us some insights into which patient should receive each treatment @fsabino_onco @fmassari79 @MatteoSantoniMD @JaviMolinaC @aron_project
‼️Just Out at @C_IMT Journal ‼️ RWE from @aron_project N: 524 fav-risk mRCC Sunitinib vs ICI+TKI ❌OS ⬆️PFS for ICI+TKI Sunitinib better for glandular mets ICI + TKI better for bone mets @fmassari79 @MatteoSantoniMD @SoaresAndrey @JaviMolinaC
0
3
10
RT @fmassari79: Which impact of time-of-day administration of immunotherapy on survival in metastatic #rcc ? Out now our meta-analysis @fs…
0
3
0
Is the time-of-day matters for #mRCC patients receiving ICI?
‼️Just out at the @MetastasisRS Journal….. Time-of-day ICI administration and survival in mRCC patients…. Congrats for the interesting data #alessandrorizzo @vmollica7 @SoaresAndrey @fmassari79 @MatteoSantoniMD
0
0
1
🚨 this is not an IO-naive trial! 🚨 And we all known that nivo/ipi isn’t a good choice for ICI progressors
Results from the FRACTION-RCC trial: Nivolumab + Relatlimab (NIVO+RELA) vs Nivolumab + Ipilimumab (NIVO+IPI) in IO-naive aRCC patients. -ORR: 30% (NIVO+RELA) vs 20% (NIVO+IPI) -PFS @ 24 wks: 43% vs 49% -Grade 3-4 AEs: 13% vs 33% #Oncology #Cancer #Research @OncoAlert @ESMO_Open @DrChoueiri @kidneycan @KidneyCancer @myESMO
0
1
5
Aron-3 RWE confirm the efficacy of apalutamide in clinical practice for #mHSPC @aron_project
Out now on @EurUrolOncol the first ARON-3 manuscript by @aron_project about the global real world of apalutamide in mHSPC Thanks to @MatteoSantoniMD @PasRescigno @SoaresAndrey and all Aron Team! @Unibo @AIOMtweet
0
1
3
Interesting data! Congrats my friends for another important work!
Is sex (female or male) a risk factor for immune-mediated AEs in patients receiving ICI?! Just out at @SciReports our systematic review and meta-analysis. @EvidenceRobot Congrats @fmassari79 @vmollica7 @DenizCanGuven1
0
0
4
So proud to be part of this huge effort and colaboration. Thank you #Aron family! @PCFnews @KidneyCancer @LACOG_group @MatteoSantoniMD @fmassari79 @fsabino_onco
Curious about the 𝗔𝗥𝗢𝗡 𝗽𝗿𝗼𝗷𝗲𝗰𝘁? 🎥Watch the video and see how we're shaping tomorrow. Let us know your thoughts below👇
0
1
4
Important data from Brazilian Public Health System (#SUS). It’s possible to optimize tx in advanced PC pts to deliver better drugs and treatments. It’s time to rediscuss the cancer treatment pathway in the #SUS and the role of pricing drugs in 🇧🇷 @minsaude @gov_mcti @LulaOficial
‼️Just out in @JCOGO_ASCO By optimizing medical procedures and financial resources we can guarantee access to better treatments for patients with mHSPC in developing countries. @SoaresAndrey @Prof_Nick_James @DrRanaMcKay @asasse @HerchenhornD @samydana
0
0
1
@RenoHemonc @BertrandTOMBAL @Silke_Gillessen @neerajaiims @DrRanaMcKay @AzadOncology @DrAndreFay @fedelosco @Prof_Nick_James The OS benefit only in a press release. Maybe at GUCASYM next year. And hope that we have the split data too
0
0
4
No te lo pierdas! Faltan pocos días para uno de los mejores congresos en urooncología @UroTarget @LACOG_group
Falta muy poco para los 9 años de @UroTarget. El gran @SoaresAndrey estará con nosotros para continuar creciendo en #LATAM. @LACOG_group @aaoncoclinica @Blatam_urology
0
3
18
Rock stars! 🚀 @LACOG_group
Spanish speakers at 🇧🇷. I feel lucky to share my passion with these incredible people @LauBernalOnc @raymanneh @drenriquegrande
@LACOG_group @UroTarget
0
2
13
@fsabino_onco @LACOG_group @LauBernalOnc @raymanneh @BourlonMaite @fedelosco @drenriquegrande Missed you my friend! Unfortunately you couldn't come
1
0
3
RT @mflazzaro_gu: Estamos cerca. UroTarget 2024 / 31 Oct-2 Nov. Mendoza, ARG @aaoncoclinica @UroTarget
0
9
0
Happy to be in one of the most important GU meetings!
ᴛʀᴇᴀᴛᴍᴇɴᴛ ʟᴀɴᴅꜱᴄᴀᴘᴇ ɪɴ ᴜʀᴏᴛʜᴇʟɪᴀʟ ᴄᴀʀᴄɪɴᴏᴍᴀ / 𝗨𝗿𝗼𝗧𝗮𝗿𝗴𝗲𝘁 𝟮𝟬𝟮𝟰. We see you soon in Mendoza @tompowles1
1
4
13